lisdexamfetamine dimesylate (Elvanse®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013001022
English
Authors' recommendations:
Lisdexamfetamine dimesylate (Elvanse®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged six years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/188
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Dextroamphetamine
- Child
- Attention Deficit Disorder with Hyperactivity
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.